



(51) International Patent Classification:
A61K 51/04 (2006.01) *G01N 33/60* (2006.01)

(21) International Application Number:
PCT/IB2009/007562

(22) International Filing Date:
27 October 2009 (27.10.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
08291013.4 28 October 2008 (28.10.2008) EP

(71) Applicants (for all designated States except US):
SANOFI-AVENTIS [FR/FR]; 174 avenue de France,
F-75013 Paris (FR). **COMMISSARIAT A L'ENERGIE
ATOMIQUE C.E.A.** [FR/FR]; Bâtiment Le ponant
D-25, rue Leblanc, F-75015 Paris (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BENAVIDES, Je-
sus** [ES/FR]; c/o Sanofi-Aventis, Patent Department, 174,
Avenue de France, F-75013 Paris (FR). **BOUTIN, Hervé**
[FR/GB]; 8 Hawphom drive, Manchester M191GX (GB).
CASTEL, Marie-Noëlle [FR/FR]; c/o Sanofi-Aventis,
Patent Department, 174, Avenue de France, F-75013
Paris (FR). **DAMONT, Annelaure** [FR/FR]; 13 rue de la
tour, F-78117 Châteaufort (FR). **DOLLE, Frédéric** [FR/
FR]; 10, allée de Villeneuve, F-91940 Gometz-le-Châtel
(FR). **HANTRAYE, Philippe** [FR/FR]; 8 Allée Jean
François de la Pérouse, F-91420 Morangis (FR). **MAR-
GUET, Frank** [FR/FR]; c/o Sanofi-Aventis, Patent De-
partment, 174, Avenue de France, F-75013 Paris (FR).
ROONEY, Thomas [GB/FR]; c/o Sanofi-Aventis, Patent
Department, 174, Avenue de France, F-75013 Paris (FR).
RIVRON, Luc [FR/FR]; c/o Sanofi-Aventis, Patent De-

partment, 174, Avenue de France, F-75013 Paris (FR).
TAVITIAN, Bertrand [FR/FR]; 186 rue de Vaugirard,
F-75015 Paris (FR). **THOMINIAUX, Cyrille** [FR/FR];
12 rue de la République, F-78470 Saint Rémy les
Chevreuse (FR).

(74) Agent: **QUELLARI, Mylène**; Sanofi-aventis, Départe-
ment Brevets, 174 avenue de France, F-75013 Paris (FR).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD,
SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: USE OF 7-CHLORO-N,N,5-TRIMETHYL-4-OXO-3-PHENYL-3,5-DIHYDRO-4H-PYRIDAZINO[4,5-B]INDOLE-1-ACETAMIDE AS A BIOMARKER OF PERIPHERAL BENZODIAZEPINE RECEPTOR LEVELS

(57) Abstract: Use of a radiolabelled form of 7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide as a biomarker for the detection, in an individual, of PBR levels associated with normal and pathological conditions. Method for the detection of PBR levels associated with normal and pathological conditions. Diagnostic kit.

